nach oben

International Journal of Clinical Pharmacy

Erschienen in:

24.09.2020 | COVID-19 | Review Article Zur Zeit gratis

The therapeutic effects of traditional chinese medicine on COVID-19: a narrative review

verfasst von: Can Wang, Shusen Sun, Xuansheng Ding

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Background The Coronavirus Disease 2019 (COVID-19) is a new, highly infective virus. In the absence of specific vaccines and antiviral drugs, the China National Health Commission has released a series of COVID-19 treatment guidelines, which include symptomatic treatment, antiviral treatment, and traditional Chinese medicines (TCM). Aim of the review To analyze and summarize the role of TCMs in the treatment of COVID-19. Methods Relevant studies on TCMs related to the study aim were undertaken through a literature search to synthesize the extracted data. Results The China National Health Commission guidelines recommend 15 oral and injectable TCMs for COVID-19. Studies on TCMs have demonstrated that these compounds possess broad-spectrum antiviral and antibacterial properties, and they have certain advantages in the treatment of viral pneumonia and other emergent infectious diseases. Many TCMs also have potent anti-inflammatory and immunomodulatory effects. Treatment based on syndrome differentiation is one of the significant features in TCM. TCM compounds contain a variety of active ingredients that have proven multi-target effects, making it difficult for viruses to develop drug resistance. A variety of clinical pathways are involved in the actions of these TCMs. These properties allow TCMs to be used in the treatment of COVID-19. Conclusion TCMs have been widely used in the treatment of COVID-19 in China. The unique properties of TCM compounds allow TCMs to have a role in the management of COVID-19.

Hick JL, Biddinger PD. Novel coronavirus and old lessons—preparing the health system for the pandemic. N Engl J Med. 2020;382(20):e55.PubMed

World Health Organize (WHO). WHO coronavirus disease (COVID-19) Dashboard [Internet]. Geneva: WHO (2020), August 7. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200505covid-19-sitrep-106.pdf?sfvrsn=47090f63_2.

The General Office of the National Health and Health Commission and the Office of the State Administration of Traditional Chinese Medicine. Notice on printing and distributing pneumonia diagnosis and treatment program for new coronavirus infection (Trial version 4) [Internet]. Beijing: China; 2020 January 28. www.gov.cn/zhengce/zhengceku/2020-01/28/content_5472673.htm. ISBN: National Health Office Medical Letter (2020) No. 77

The General Office of the National Health and Health Commission and the Office of the State Administration of Traditional Chinese Medicine. Notice on printing and distributing pneumonia diagnosis and treatment program for new coronavirus infection (trial version 5) [Internet]. Beijing: China; 2020 February 5. https://www.gov.cn/zhuanti/2020-02/09/content_5476407.htm. ISBN: National Health Office Medical Letter (2020) No. 117

The General Office of the National Health and Health Commission and the Office of the State Administration of Traditional Chinese Medicine. Notice on printing and distributing pneumonia diagnosis and treatment program for new coronavirus infection (trial version 6) [Internet]. Beijing: China; 2020 February 19. https://www.gov.cn/zhengce/zhengceku/2020-02/05/content_5474791.htm. ISBN: National Health Office Medical Letter (2020) No. 145

The General Office of the National Health and Health Commission and the Office of the State Administration of Traditional Chinese Medicine. Notice on printing and distributing pneumonia diagnosis and treatment program for new coronavirus infection (trial version 7) [Internet]. Beijing: China; 2020 March 4. https://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.htm. ISBN: National Health Office Medical Letter (2020) No. 184

World Health Organization. Regional Office for the Western Pacific. WHO international standard terminologies on traditional medicine in the Western Pacific Region. Geneva: WHO; 2007. ISBN: 9789290612487

World Federation of Chinese Medicine Societies. International standard Chinese–English basic nomenclature of Chinese Medicine. Beijing: China; 2008.

Li D, Che Z. TCM syndrome type analysis of 58 cases of new crown pneumonia in Wuhan square cabin hospital, China. Trace Elem Health Res. 2020;5:40-1.

10.

Ma J, Chen M, Wang YG. Summary of TCM syndrome and treatment of novel coronavirus pneumonia, China. Beijing. Tradit Chin Med J. 2020;39(02):95–101.

11.

Zhang Q, Cao F, Wang Y, Xu X, Sun Y, Li J, et al. The efficacy and safety of Jinhua Qinggan granule (JHQG) in the treatment of coronavirus disease 2019 (COVID-19): a protocol for systematic review and meta analysis. Medicine (Baltim). 2020;99(24):e20531.

12.

Qi JP, Qi XY, Wang XJ. The effect of different doses of Jinhua Qinggan granule on influenza and its effect on serum cytokine, China, Mod Med J. 2016;44(12):1664–9.

13.

Duan C, Xia WG, Zheng CJ, Sun GB, Li ZL, Li QL, et al. Clinical observation of Jinhua Qinggan granule to treat COVID-19. J Tradit Chin Med. 2020;61:1–5.

14.

Jia W, Wang C, Wang Y, Pan G, Jiang M, Li Z, et al. Qualitative and quantitative analysis of the major constituents in Chinese medical preparation Lianhua-Qingwen capsule by UPLC-DAD-QTOF-MS. Sci World J. 2015;2015:731765.

15.

Liu CY, Li XQ, Cai SQ. Progress in pharmacology and clinical research of Lianhua Qingwen capsules, China. Pharm Clin Chin Mater Med. 2010;26(06):84–85+21.

16.

Xia JW, Chen XJ, Zhang J, Zhou ZW. Experimental investigation of the effect of Lianhuaqingwen Capsule on the rat models of chronic obstructive pulmonary disease, China. Fudan Univ J Med Sci. 2008;03:441–4.

17.

Ding Y, Zeng L, Li R, Chen Q, Zhou B, Chen Q, et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med. 2017;17(1):130.PubMedPubMedCentral

18.

Yao KT, Liu MY, Li X, Huang JH, Cai HB. Retrospective clinical analysis of traditional Chinese medicine Lianhua Qingwen in treating new coronavirus pneumonia, China. Chin J Exp Tradit Med Formul. 2020;26(11):8–12.

19.

Cheng DZ, Wang WJ, Li Y, Wu XD, Zhou B, Song QY. Analysis of the efficacy of Chinese medicine Lianhua Qingwen in 51 patients with new coronavirus pneumonia: a multicenter retrospective study, China, Tianjin. Tradit Chin Med J. 2020;37(05):509–16.

20.

Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, et al. Efficacy and safety of Lianhua Qingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine. 2020;16:153242.

21.

Liu X, Zhang H, Xu J, Gong S, Han Y, Zhang T, et al. Identification of absorbed components and their metabolites in rat plasma after oral administration of Shufeng Jiedu capsule using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun Mass Spectrom. 2019;33(19):1494–501.PubMed

22.

Ji S, Bai Q, Wu X, Zhang DW, Wang S, Shen JL, et al. Unique synergistic antiviral effects of Shufeng Jiedu capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease. Biomed Pharmacother. 2020;121:109652.PubMed

23.

Ji QJ, Shan RY, Deng SM, Tian YY, Chai W, Huang H, et al. Effect of Shu Feng Jiedu capsule on compliance of OSAHS patients before and after nCPAP treatment, China. World J Integ Tradit Western Med. 2019;14(05):692–4.

24.

Ma L, Huang Y, Hou YB, Zhang DD, Zhang YP, Liu J, et al. Study on mechanism for immunoregulation of Shufeng Jiedu Capsule, Chiana. Drug Eval Res. 2019;42(09):1763–8.

25.

Yang QW, Li Q, Zhang J, Xu Q, Yang X, Li ZY, et al.. Crystal structure and anti-inflammatory and anaphylactic effects of andrographlide sulphonate E in Xiyanping, a traditional Chinese medicine injection. J Pharm Pharmacol. 2019;71(2):251–9.PubMed

26.

Liu YH, Feng F, Xie N. Advances in research on the anti-tumor, anti-pyretic and anti—inflammatory activity of andrographolide derivatives, China. Northwest Pharm J. 2013;28(1):95–8.

27.

Shan M, Huang Y, Cui ZZ. Study on the effect of intravenous dripping of andrographolide in stabilizing body temperature of children with acute bronchial pneumonia, China. Chin Pediatr Integr Tradit Western Med. 2018;10(2):146–9.

28.

Ding Y, Chen LZ, Wu WJ, Yang J, Yang ZF, Liu SW. Andrographolide inhibits influenza A virus-induced inflammation in a murine model through NF-κB and JAK-STAT signaling pathway. Microb Infect. 2017;19(12):605–15.

29.

Cai N, Li YP, Zhou GJ, Xin C, Xie J, Zhou HH, et al. Theoretical basis and effect characteristics of andrographolide against COVID-19, China. Chin Tradit Herb Drug. 2020;51(05):1159–66.

30.

Wang C, Shi QP, Ding F, Yu ML, Tang W, Cheng JQ. Reevaluation of the post-marketing safety of Xuebijing injection based on real-world and evidence-based evaluations. Biomed Pharmacother. 2019;109:1523–31.PubMed

31.

Diao YF, Zhang SJ, Zhao WY, Sun HT, Zhang S, Sun L. Effect of Xuebijing Injection on expression of interleukin-6 and tumor necrosis factor-α in patients with severe pneumonia, China. Chin Tradit Herb Drug. 2017;48(06):1188–91.

32.

Zhang CY, Zhang S, Wang W, Jiang XQ. Clinical observation of Xuebijing in the treatment of COVID-19, China. Chin J Hosp Pharm. 2020;40(09):964–7.

33.

Sun K. The study of anti-inflammation mechanism of Reduning injection based on signaling pathways and discussion of disease therapy. Xian: Nothwest university; 2015.

34.

Yan Y, Fan FJ, Zhao J, Bao JY, Feng LX. Clinical study on Reduning injection combined with biapenem in treatment of severe pneumonia. Drugs Clinic. 2019;34(12):3598–602.

35.

Li HB, Yu Y, Wang ZZ, Xiao W, Yao XS. Research on antiviral constituents in Re–Du–Ning Injection (I),China. Chin Tradit Herb Drug. 2014;45(12):1682–8.

36.

Zhang F, Sun L, Gao SH, Chen WS, Chai YF. LC-MS/MS analysis and pharmacokinetic study on five bioactive constituents of Tanreqing injection in rats. Chin J Nat Med. 2016;14(10):769–75.PubMed

37.

Zhang B. Observation of therapeutic effect of tanreqing injection combined with ceftizoxime sodium for lower respiratory tract infection, China. Chin Tradit Herb Drug. 2009;40(6):947–8.

38.

Zhu H, Chen M, Shi X, Shi C, Huang C. Material basis studies of anti-Influenza A active ingredients in Tanreqing injection. Biomed Chromatogr. 2018;32(2):e4097.

39.

Wu Z, Chen C, Miao Y, Liu Y, Zhang Q, Li R, et al. Baicalin attenuates mycoplasma gallisepticum-induced inflammation via inhibition of the TLR2-NF-κB pathway in chicken and DF-1 Cells. Infect Drug Resist. 2019;20(12):3911–23.

40.

Kong Y, Wu HW, Chen Y, Lai S, Yang ZM, Chen JS. Mechanism of Tanreqing Injection on treatment of coronavirus disease 2019 based on network pharmacology and molecular docking. China Chin Tradit Herb Drug. 2020;51(07):1785–94.

41.

Pan W, Yang L, Feng W, Lin L, Li C, Liu W, et al. Determination of five sesquiterpenoids in Xingnaojing injection by quantitative analysis of multiple components with a single marker. J Sep Sci. 2015;38(19):3313–23.PubMed

42.

Zhang AX. Application progress of Xingnaojing injection in clinical emergency, China. Mod J Integr Tradit Chin Western Med. 2013;22(17):1937–8.

43.

Wu XL. Observation of anti-hyperthermia effect of Xingnaojing injection on adult upper respiratory tract infection, China. Shandong Med J. 2009;49(28):108–108.

44.

Xu ZF, Wanf LJ, Yu ZM. Clinical Study on the intervention effect of Xingnaojing injection on acute infectious fever, China. Lingnan J Emerg Med. 2013;18(1):36–7.

45.

Zhang JJ, Zhu ZY, Zhang J. The observation on therapeutic efficacy of antihyperthermal and revival effects of Xingnaojing Injection in treatment for severe craniocerebral injuries, China. Chin J Integ Tradit Western Med in Intensive Crit Care. 1999;6(1):5–7.

46.

Wang J, Yang GT, Qiao LF. Effects of Xingnaojing injection on lipopolysaccharide-induces nuclear factor-kB activation and cytokine production in rat alveolar macrophages, China. Chin J Integr Tradit Western Med Int Crit Care. 2008;15(4):212–5.

47.

Xie D, Hu J, Chen XH. Effect of Xingnaojing injection on the serum TNF-α, CRP levels and immune function of elderly patients with mycoplasma pneumoniae pneumonia*, China. Prog Mod Biomed. 2016;16(16):3112–5.

48.

Yin HY, Zhang R, Li BH. Effects of Xingnaojing injection on serum cytokines in patients with severe pneumonia in ICU, China. Chin J Clin Pharm Ther. 2007;12(12):1428–31.

49.

Liu C, Hou Y, Wang X, Zhao Z, Liu Z, Zhai J, et al. Clinical assessment of Shenfu injection loading in the treatment of patients with exacerbation of chronic heart failure due to coronary heart disease: study protocol for a randomized controlled trial. Trials. 2015;21(16):222.

50.

Zhang N, Liu JH, Qiu ZL, Ye YP, Zhang J, Lou TZ. Shenfu injection for improving cellular immunity and clinical outcome in patients with sepsis or septic shock. Am J Emerg Med. 2017;35(1):1–6.PubMed

51.

Wang XJ, He CF, Cai YH, Sun DZ, Hu GY, Zhou J. Shen fu injection for patients with septic shock: protocol for an updated systematic review. Medicine (Baltimore). 2019;98(38):e17004.

52.

Yu R. Clinical observation on infantile bacterial pneumonia treated by Shenfu injection, China. Chin Tradit Herb Drug. 2004;35(12):1397–8.

53.

Hu Q, Yang WY, Long J. Effect of Shenfu injection on procalcitonin and immunoglobulin in elderly patients with chronic lung infection, China. J Emerg Tradit Chin Med. 2013;22(5):829–30.

54.

Li N, Sheng KJ, Peng GX. Effect of Shenfu injection assisted with antibiotics on the subsided time of clinical symptoms, endothelial cell damage factor and pulmonary function in elderly patients with severe pneumonia, China. Prac Geriatr. 2019;33(8):764–7.

55.

Li P. Hemodynamic effects of severe pneumonia by Shenfu injection, China. Guide Chin Med. 2012;10(33):52–3.

56.

Liu X, Ai F, Li H, Xu Q, Mei LY, Miao JF, et al. Anti-Inflammatory effects of Shenfu injection against acute lung injury through inhibiting HMGB1-NF-kappaB pathway in a rat model of endotoxin shock. Evid Based Complement Altern Med. 2019;3(2019):9857683.

57.

Zhang MY, Ji XF, Wang S, Li CS. Shen-fu injection attenuates postresuscitation lung injury in a porcine model of cardiac arrest. Resuscitation. 2012;83(9):1152–8.PubMed

58.

Haijiang Z, Yongjiang W, Yiyu C. Analysis of 'SHENMAI' injection by HPLC/MS/MS. J Pharm Biomed Anal. 2003;31(1):175–83.PubMed

59.

Liu WY, Zhang JW, Yao XQ, Jiang C, He JC, Ni P, et al. Shenmai injection enhances the cytotoxicity of chemotherapeutic drugs against colorectal cancers via improving their subcellular distribution. Acta Pharmacol Sin. 2017;38(2):264–76.PubMed

60.

Li L, Yang DL, Li JH, Niu L, Chen Y, Zhao X, et al. Investigation of cardiovascular protective effect of Shenmai injection by network pharmacology and pharmacological evaluation. BMC Complement Med Ther. 2020;20(1):112.PubMedPubMedCentral

61.

Fan XC, Tu S, Cao FB. Effect of Shenmai injection on inflammatory factors in patients with severe pneumonia, China. Hebei Med. 2018;24(10):1656–9.

62.

Wang YF, Zhou Y, Li GF. Correlation between the dose of shenmai injection and the immune function and therapeutic effect of ventilator associated pneumonia, China. Chin J Mod Appl Pharm. 2019;36(24):3085–9.

63.

Shen LE, Du QS, Zhao HL. Effect of Shenmai injection on immune function of patients with sepsis, China. Chin J Clin Ration Drug Use. 2014;7(1):67–8.

64.

Guo Q, Zhang JQ, Shi R. Therapeutic effect of Shengmai injection combined with conventional Western medicine on systemic inflammatory response syndrome and its effect on vasoactive transmitter, China. Mod J Integr Tradit Chin Western Med. 2018;27(7):743–6.

65.

Xu JN, Zhou CH, Huang SZ. Comparative observation on treatment of elderly pulmonary infection with multiple organ failure by adding Shengmai injection(Chinese). J Modern Clin Med. 1996;22(1):31–2.

66.

Fei DL, Wang HJ, Su YG, Wang L. Effect of Schisandra sphenanthera polysaccharide on immune function of immunosuppressive mice induced by cyclophosphamide. China Feed Res. 2014;15:89–91.

67.

Dong L, Li YQ, Yang SJ, Liu MN, Liu JL. A case study on syndrome differentiation and treatment of new coronavirus pneumonia. China Pharm Clin Chin Mater Med. 2020;36(02):69–71.

68.

Ang L, Song E, Lee HW, Lee MS. herbal medicine for the treatment of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2020;9(5):1583.PubMedCentral

69.

Zhao L, Zhao YF, Yuan ZY, Sun JB. Clinical application of Zhang Zhongjing's theory of ″Treating Different Diseases with Same Method″. China Tradit Chin Med Res. 2020;33(02):49–52.

70.

Xinhuanet. Chinese medicine fights the "epidemic": from participant to main force [Internet]. Yu Y, editor. Shanghai: Xinhua News Agency. [cited 2020 July 28]. https://www.xinhuanet.com/fortune/2020-02/19/c_1125595276.htm.

71.

Meng L, Qiu F, Sun S. Providing pharmacy services at cabin hospitals at the coronavirus epicenter in China. Int J Clin Pharm. 2020;42(2):305–8.PubMed

72.

Liu S, Luo P, Tang M, Hu Q, Polidoro JP, Sun S, et al. Providing pharmacy services during the coronavirus pandemic. Int J Clin Pharm. 2020;42(2):299–304.PubMed

Titel: The therapeutic effects of traditional chinese medicine on COVID-19: a narrative review
verfasst von: Can Wang
Shusen Sun
Xuansheng Ding
Publikationsdatum: 24.09.2020
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: International Journal of Clinical Pharmacy / Ausgabe 1/2021
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI: https://doi.org/10.1007/s11096-020-01153-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The therapeutic effects of traditional chinese medicine on COVID-19: a narrative review

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Voluntarily reported prescribing, monitoring and medication transfer errors in intensive care units in The Netherlands

Managing medicines in the time of COVID-19: implications for community-dwelling people with dementia

Patient satisfaction with community pharmacist-led anticoagulation management services and its relationship with patient characteristics in New Zealand

Patients’ perceptions of medicines information received at hospital discharge in Norway: a qualitative interview study

Allergic rhinitis characterization in community pharmacy customers: a cross-sectional study

Correction to: Learning the effects of psychotropic drugs during pregnancy using real‑world safety data: a paradigm shift toward modern pharmacovigilance

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin